Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

530 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
KIF5B-RET fusions in lung adenocarcinoma.
Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T. Kohno T, et al. Among authors: yokota j. Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644. Nat Med. 2012. PMID: 22327624 Free PMC article.
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, Watanabe S, Tamura T, Yokota J, Suzuki K, Asamura H, Furuta K, Tsuda H. Kozu Y, et al. Among authors: yokota j. Lung Cancer. 2011 Jul;73(1):45-50. doi: 10.1016/j.lungcan.2010.11.003. Epub 2010 Dec 3. Lung Cancer. 2011. PMID: 21129809
Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.
Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S, Watanabe S, Sakamoto H, Kumamoto K, Takenoshita S, Gotoh N, Mizuno H, Sarai A, Kawano S, Yamaguchi R, Miyano S, Yokota J. Okayama H, et al. Among authors: yokota j. Cancer Res. 2012 Jan 1;72(1):100-11. doi: 10.1158/0008-5472.CAN-11-1403. Epub 2011 Nov 11. Cancer Res. 2012. PMID: 22080568
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe S, Nokihara H, Yasuda K, Hiramoto M, Nammo T, Ishigame T, Schetter AJ, Okayama H, Harris CC, Kim YH, Mishima M, Yokota J, Yoshida T, Kohno T. Nakaoku T, et al. Among authors: yokota j. Clin Cancer Res. 2014 Jun 15;20(12):3087-93. doi: 10.1158/1078-0432.CCR-14-0107. Epub 2014 Apr 11. Clin Cancer Res. 2014. PMID: 24727320 Free PMC article.
Development of lung adenocarcinomas with exclusive dependence on oncogene fusions.
Saito M, Shimada Y, Shiraishi K, Sakamoto H, Tsuta K, Totsuka H, Chiku S, Ichikawa H, Kato M, Watanabe S, Yoshida T, Yokota J, Kohno T. Saito M, et al. Among authors: yokota j. Cancer Res. 2015 Jun 1;75(11):2264-71. doi: 10.1158/0008-5472.CAN-14-3282. Epub 2015 Apr 8. Cancer Res. 2015. PMID: 25855381
Frequent EGFR mutations in brain metastases of lung adenocarcinoma.
Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E, Yokota J. Matsumoto S, et al. Among authors: yokota j. Int J Cancer. 2006 Sep 15;119(6):1491-4. doi: 10.1002/ijc.21940. Int J Cancer. 2006. PMID: 16642476 Free article.
530 results